We feel now is a pretty good time to analyse CollPlant Biotechnologies Ltd.’s (NASDAQ:CLGN) business as it appears the company may be on the cusp of a considerable accomplishment. CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. With the latest financial year loss of US$17m and a trailing-twelve-month loss of US$12m, the US$12m market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is CollPlant Biotechnologies’ path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Consensus from 2 of the American Biotechs analysts is that CollPlant Biotechnologies is on the verge of breakeven. They expect the company to post a final loss in 2027, before turning a profit of US$4.9m in 2028. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 61%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
NasdaqCM:CLGN Earnings Per Share Growth February 8th 2026
Underlying developments driving CollPlant Biotechnologies’ growth isn’t the focus of this broad overview, but, bear in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
See our latest analysis for CollPlant Biotechnologies
Before we wrap up, there’s one aspect worth mentioning. CollPlant Biotechnologies currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
There are key fundamentals of CollPlant Biotechnologies which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at CollPlant Biotechnologies, take a look at CollPlant Biotechnologies’ company page on Simply Wall St. We’ve also put together a list of important factors you should look at: